← Back to Clinical Trials
Recruiting NCT00568490

NCT00568490 Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT00568490
Status Recruiting
Phase
Sponsor Stanford University
Condition Head and Neck Cancer
Study Type OBSERVATIONAL
Enrollment 200 participants
Start Date 1998-09-01
Primary Completion 2026-04-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Tumor biopsyPhlebotomy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 200 participants in total. It began in 1998-09-01 with a primary completion date of 2026-04-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Eligibility Criteria

Inclusion Criteria: * Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck. * Able to sign a Stanford IRB approved consent form Exclusion criteria: * Refuse or unable to sign an IRB approved consent form. * Refuse to be contacted in the future for follow up.

Contact & Investigator

Central Contact
Principal Investigator

Quynh-Thu Le

PRINCIPAL INVESTIGATOR

Stanford University

Frequently Asked Questions

Who can join the NCT00568490 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Head and Neck Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT00568490 currently recruiting?

Yes, NCT00568490 is actively recruiting participants. Contact the research team at Rad-onc-ccto@lists.stanford.edu for enrollment information.

Where is the NCT00568490 trial being conducted?

This trial is being conducted at Stanford, United States.

Who is sponsoring the NCT00568490 clinical trial?

NCT00568490 is sponsored by Stanford University. The principal investigator is Quynh-Thu Le at Stanford University. The trial plans to enroll 200 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology